Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Identifieur interne : 003433 ( Ncbi/Merge ); précédent : 003432; suivant : 003434Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Auteurs : Antoni Ribas [États-Unis] ; Omid Hamid [États-Unis] ; Adil Daud [États-Unis] ; F Stephen Hodi [États-Unis] ; Jedd D. Wolchok [États-Unis] ; Richard Kefford [Australie] ; Anthony M. Joshua [Canada] ; Amita Patnaik ; Wen-Jen Hwu [États-Unis] ; Jeffrey S. Weber [États-Unis] ; Tara C. Gangadhar [États-Unis] ; Peter Hersey [Australie] ; Roxana Dronca [États-Unis] ; Richard W. Joseph [États-Unis] ; Hassane Zarour [États-Unis] ; Bartosz Chmielowski [États-Unis] ; Donald P. Lawrence [États-Unis] ; Alain Algazi [États-Unis] ; Naiyer A. Rizvi [États-Unis] ; Brianna Hoffner [États-Unis] ; Christine Mateus [France] ; Kevin Gergich [États-Unis] ; Jill A. Lindia [États-Unis] ; Maxine Giannotti [États-Unis] ; Xiaoyun Nicole Li [États-Unis] ; Scot Ebbinghaus [États-Unis] ; S Peter Kang [États-Unis] ; Caroline Robert [France]Source :
- JAMA [ 1538-3598 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Algorithmes, Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antinéoplasiques (usage thérapeutique), Calendrier d'administration des médicaments, Femelle, Humains, Jeune adulte, Mâle, Mélanome (anatomopathologie), Mélanome (mortalité), Mélanome (traitement médicamenteux), Récepteur-1 de mort cellulaire programmée (antagonistes et inhibiteurs), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Taux de survie, Tumeurs cutanées (anatomopathologie), Tumeurs cutanées (mortalité), Tumeurs cutanées (traitement médicamenteux), Évolution de la maladie.
- MESH :
- anatomopathologie : Mélanome, Tumeurs cutanées.
- antagonistes et inhibiteurs : Récepteur-1 de mort cellulaire programmée.
- mortalité : Mélanome, Tumeurs cutanées.
- traitement médicamenteux : Mélanome, Tumeurs cutanées.
- usage thérapeutique : Anticorps monoclonaux, Anticorps monoclonaux humanisés, Antinéoplasiques.
- Adulte, Adulte d'âge moyen, Algorithmes, Calendrier d'administration des médicaments, Femelle, Humains, Jeune adulte, Mâle, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Taux de survie, Évolution de la maladie.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antineoplastic Agents (therapeutic use), Disease Progression, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Male, Melanoma (drug therapy), Melanoma (mortality), Melanoma (pathology), Middle Aged, Programmed Cell Death 1 Receptor (antagonists & inhibitors), Skin Neoplasms (drug therapy), Skin Neoplasms (mortality), Skin Neoplasms (pathology), Survival Rate, Treatment Outcome, Young Adult.
- MESH :
- chemical , antagonists & inhibitors : Programmed Cell Death 1 Receptor.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents.
- drug therapy : Melanoma, Skin Neoplasms.
- mortality : Melanoma, Skin Neoplasms.
- pathology : Melanoma, Skin Neoplasms.
- Adult, Aged, Aged, 80 and over, Algorithms, Disease Progression, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Survival Rate, Treatment Outcome, Young Adult.
Abstract
The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.
DOI: 10.1001/jama.2016.4059
PubMed: 27092830
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001F75
- to stream PubMed, to step Curation: 001F50
- to stream PubMed, to step Checkpoint: 001F50
Links to Exploration step
pubmed:27092830Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.</title><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology and Oncology, University of California-Los Angeles, Los Angeles.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Hematology and Oncology, University of California-Los Angeles</wicri:orgArea></affiliation></author><author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Daud, Adil" sort="Daud, Adil" uniqKey="Daud A" first="Adil" last="Daud">Adil Daud</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology/Oncology, University of California-San Francisco, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Department of Hematology/Oncology, University of California-San Francisco</wicri:orgArea></affiliation></author><author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D" last="Wolchok">Jedd D. Wolchok</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Kefford, Richard" sort="Kefford, Richard" uniqKey="Kefford R" first="Richard" last="Kefford">Richard Kefford</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, Australia7Department of Clinical Medicine, Macquarie University, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, Australia7Department of Clinical Medicine, Macquarie University, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Joshua, Anthony M" sort="Joshua, Anthony M" uniqKey="Joshua A" first="Anthony M" last="Joshua">Anthony M. Joshua</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Patnaik, Amita" sort="Patnaik, Amita" uniqKey="Patnaik A" first="Amita" last="Patnaik">Amita Patnaik</name><affiliation><nlm:affiliation>Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio.</nlm:affiliation><wicri:noCountry code="subField">San Antonio</wicri:noCountry></affiliation></author><author><name sortKey="Hwu, Wen Jen" sort="Hwu, Wen Jen" uniqKey="Hwu W" first="Wen-Jen" last="Hwu">Wen-Jen Hwu</name><affiliation wicri:level="3"><nlm:affiliation>Department of Melanoma, The University of Texas MD Anderson Cancer Center, Houston.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><wicri:orgArea>Department of Melanoma, The University of Texas MD Anderson Cancer Center</wicri:orgArea></affiliation></author><author><name sortKey="Weber, Jeffrey S" sort="Weber, Jeffrey S" uniqKey="Weber J" first="Jeffrey S" last="Weber">Jeffrey S. Weber</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Gangadhar, Tara C" sort="Gangadhar, Tara C" uniqKey="Gangadhar T" first="Tara C" last="Gangadhar">Tara C. Gangadhar</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology and Oncology, Abramson Cancer Center at the University of Pennsylvania, Philadelphia.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName><wicri:orgArea>Division of Hematology and Oncology, Abramson Cancer Center at the University of Pennsylvania</wicri:orgArea></affiliation></author><author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Dronca, Roxana" sort="Dronca, Roxana" uniqKey="Dronca R" first="Roxana" last="Dronca">Roxana Dronca</name><affiliation wicri:level="2"><nlm:affiliation>Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Division of Medical Oncology, Mayo Clinic, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Joseph, Richard W" sort="Joseph, Richard W" uniqKey="Joseph R" first="Richard W" last="Joseph">Richard W. Joseph</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Hematology/Oncology, Mayo Clinic, Jacksonville</wicri:cityArea></affiliation></author><author><name sortKey="Zarour, Hassane" sort="Zarour, Hassane" uniqKey="Zarour H" first="Hassane" last="Zarour">Hassane Zarour</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Medicine, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Chmielowski, Bartosz" sort="Chmielowski, Bartosz" uniqKey="Chmielowski B" first="Bartosz" last="Chmielowski">Bartosz Chmielowski</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology and Oncology, University of California-Los Angeles, Los Angeles.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Hematology and Oncology, University of California-Los Angeles</wicri:orgArea></affiliation></author><author><name sortKey="Lawrence, Donald P" sort="Lawrence, Donald P" uniqKey="Lawrence D" first="Donald P" last="Lawrence">Donald P. Lawrence</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology/Oncology, Massachusetts General Hospital, Boston.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Hematology/Oncology, Massachusetts General Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Algazi, Alain" sort="Algazi, Alain" uniqKey="Algazi A" first="Alain" last="Algazi">Alain Algazi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology/Oncology, University of California-San Francisco, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Department of Hematology/Oncology, University of California-San Francisco</wicri:orgArea></affiliation></author><author><name sortKey="Rizvi, Naiyer A" sort="Rizvi, Naiyer A" uniqKey="Rizvi N" first="Naiyer A" last="Rizvi">Naiyer A. Rizvi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Hoffner, Brianna" sort="Hoffner, Brianna" uniqKey="Hoffner B" first="Brianna" last="Hoffner">Brianna Hoffner</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Mateus, Christine" sort="Mateus, Christine" uniqKey="Mateus C" first="Christine" last="Mateus">Christine Mateus</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud</wicri:regionArea><wicri:noRegion>Villejuif Paris-Sud</wicri:noRegion><wicri:noRegion>Villejuif Paris-Sud</wicri:noRegion></affiliation></author><author><name sortKey="Gergich, Kevin" sort="Gergich, Kevin" uniqKey="Gergich K" first="Kevin" last="Gergich">Kevin Gergich</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Lindia, Jill A" sort="Lindia, Jill A" uniqKey="Lindia J" first="Jill A" last="Lindia">Jill A. Lindia</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Giannotti, Maxine" sort="Giannotti, Maxine" uniqKey="Giannotti M" first="Maxine" last="Giannotti">Maxine Giannotti</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Li, Xiaoyun Nicole" sort="Li, Xiaoyun Nicole" uniqKey="Li X" first="Xiaoyun Nicole" last="Li">Xiaoyun Nicole Li</name><affiliation wicri:level="2"><nlm:affiliation>BARDS, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>BARDS, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Ebbinghaus, Scot" sort="Ebbinghaus, Scot" uniqKey="Ebbinghaus S" first="Scot" last="Ebbinghaus">Scot Ebbinghaus</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Kang, S Peter" sort="Kang, S Peter" uniqKey="Kang S" first="S Peter" last="Kang">S Peter Kang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud</wicri:regionArea><wicri:noRegion>Villejuif Paris-Sud</wicri:noRegion><wicri:noRegion>Villejuif Paris-Sud</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27092830</idno><idno type="pmid">27092830</idno><idno type="doi">10.1001/jama.2016.4059</idno><idno type="wicri:Area/PubMed/Corpus">001F75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F75</idno><idno type="wicri:Area/PubMed/Curation">001F50</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F50</idno><idno type="wicri:Area/PubMed/Checkpoint">001F50</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001F50</idno><idno type="wicri:Area/Ncbi/Merge">003433</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.</title><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology and Oncology, University of California-Los Angeles, Los Angeles.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Hematology and Oncology, University of California-Los Angeles</wicri:orgArea></affiliation></author><author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Daud, Adil" sort="Daud, Adil" uniqKey="Daud A" first="Adil" last="Daud">Adil Daud</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology/Oncology, University of California-San Francisco, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Department of Hematology/Oncology, University of California-San Francisco</wicri:orgArea></affiliation></author><author><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D" last="Wolchok">Jedd D. Wolchok</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Kefford, Richard" sort="Kefford, Richard" uniqKey="Kefford R" first="Richard" last="Kefford">Richard Kefford</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, Australia7Department of Clinical Medicine, Macquarie University, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, Australia7Department of Clinical Medicine, Macquarie University, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Joshua, Anthony M" sort="Joshua, Anthony M" uniqKey="Joshua A" first="Anthony M" last="Joshua">Anthony M. Joshua</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Patnaik, Amita" sort="Patnaik, Amita" uniqKey="Patnaik A" first="Amita" last="Patnaik">Amita Patnaik</name><affiliation><nlm:affiliation>Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio.</nlm:affiliation><wicri:noCountry code="subField">San Antonio</wicri:noCountry></affiliation></author><author><name sortKey="Hwu, Wen Jen" sort="Hwu, Wen Jen" uniqKey="Hwu W" first="Wen-Jen" last="Hwu">Wen-Jen Hwu</name><affiliation wicri:level="3"><nlm:affiliation>Department of Melanoma, The University of Texas MD Anderson Cancer Center, Houston.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><wicri:orgArea>Department of Melanoma, The University of Texas MD Anderson Cancer Center</wicri:orgArea></affiliation></author><author><name sortKey="Weber, Jeffrey S" sort="Weber, Jeffrey S" uniqKey="Weber J" first="Jeffrey S" last="Weber">Jeffrey S. Weber</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Gangadhar, Tara C" sort="Gangadhar, Tara C" uniqKey="Gangadhar T" first="Tara C" last="Gangadhar">Tara C. Gangadhar</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology and Oncology, Abramson Cancer Center at the University of Pennsylvania, Philadelphia.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName><wicri:orgArea>Division of Hematology and Oncology, Abramson Cancer Center at the University of Pennsylvania</wicri:orgArea></affiliation></author><author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Dronca, Roxana" sort="Dronca, Roxana" uniqKey="Dronca R" first="Roxana" last="Dronca">Roxana Dronca</name><affiliation wicri:level="2"><nlm:affiliation>Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Division of Medical Oncology, Mayo Clinic, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Joseph, Richard W" sort="Joseph, Richard W" uniqKey="Joseph R" first="Richard W" last="Joseph">Richard W. Joseph</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Hematology/Oncology, Mayo Clinic, Jacksonville</wicri:cityArea></affiliation></author><author><name sortKey="Zarour, Hassane" sort="Zarour, Hassane" uniqKey="Zarour H" first="Hassane" last="Zarour">Hassane Zarour</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Medicine, University of Pittsburgh, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Chmielowski, Bartosz" sort="Chmielowski, Bartosz" uniqKey="Chmielowski B" first="Bartosz" last="Chmielowski">Bartosz Chmielowski</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology and Oncology, University of California-Los Angeles, Los Angeles.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Hematology and Oncology, University of California-Los Angeles</wicri:orgArea></affiliation></author><author><name sortKey="Lawrence, Donald P" sort="Lawrence, Donald P" uniqKey="Lawrence D" first="Donald P" last="Lawrence">Donald P. Lawrence</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology/Oncology, Massachusetts General Hospital, Boston.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Boston</settlement><region type="state">Massachusetts</region></placeName><wicri:orgArea>Department of Hematology/Oncology, Massachusetts General Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Algazi, Alain" sort="Algazi, Alain" uniqKey="Algazi A" first="Alain" last="Algazi">Alain Algazi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology/Oncology, University of California-San Francisco, San Francisco.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Department of Hematology/Oncology, University of California-San Francisco</wicri:orgArea></affiliation></author><author><name sortKey="Rizvi, Naiyer A" sort="Rizvi, Naiyer A" uniqKey="Rizvi N" first="Naiyer A" last="Rizvi">Naiyer A. Rizvi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Hoffner, Brianna" sort="Hoffner, Brianna" uniqKey="Hoffner B" first="Brianna" last="Hoffner">Brianna Hoffner</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Mateus, Christine" sort="Mateus, Christine" uniqKey="Mateus C" first="Christine" last="Mateus">Christine Mateus</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud</wicri:regionArea><wicri:noRegion>Villejuif Paris-Sud</wicri:noRegion><wicri:noRegion>Villejuif Paris-Sud</wicri:noRegion></affiliation></author><author><name sortKey="Gergich, Kevin" sort="Gergich, Kevin" uniqKey="Gergich K" first="Kevin" last="Gergich">Kevin Gergich</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Lindia, Jill A" sort="Lindia, Jill A" uniqKey="Lindia J" first="Jill A" last="Lindia">Jill A. Lindia</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Giannotti, Maxine" sort="Giannotti, Maxine" uniqKey="Giannotti M" first="Maxine" last="Giannotti">Maxine Giannotti</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Li, Xiaoyun Nicole" sort="Li, Xiaoyun Nicole" uniqKey="Li X" first="Xiaoyun Nicole" last="Li">Xiaoyun Nicole Li</name><affiliation wicri:level="2"><nlm:affiliation>BARDS, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>BARDS, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Ebbinghaus, Scot" sort="Ebbinghaus, Scot" uniqKey="Ebbinghaus S" first="Scot" last="Ebbinghaus">Scot Ebbinghaus</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Kang, S Peter" sort="Kang, S Peter" uniqKey="Kang S" first="S Peter" last="Kang">S Peter Kang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud</wicri:regionArea><wicri:noRegion>Villejuif Paris-Sud</wicri:noRegion><wicri:noRegion>Villejuif Paris-Sud</wicri:noRegion></affiliation></author></analytic><series><title level="j">JAMA</title><idno type="eISSN">1538-3598</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Algorithms</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Disease Progression</term><term>Disease-Free Survival</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Melanoma (drug therapy)</term><term>Melanoma (mortality)</term><term>Melanoma (pathology)</term><term>Middle Aged</term><term>Programmed Cell Death 1 Receptor (antagonists & inhibitors)</term><term>Skin Neoplasms (drug therapy)</term><term>Skin Neoplasms (mortality)</term><term>Skin Neoplasms (pathology)</term><term>Survival Rate</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Algorithmes</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (mortalité)</term><term>Mélanome (traitement médicamenteux)</term><term>Récepteur-1 de mort cellulaire programmée (antagonistes et inhibiteurs)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Tumeurs cutanées (anatomopathologie)</term><term>Tumeurs cutanées (mortalité)</term><term>Tumeurs cutanées (traitement médicamenteux)</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Programmed Cell Death 1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur-1 de mort cellulaire programmée</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Algorithms</term><term>Disease Progression</term><term>Disease-Free Survival</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Survival Rate</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Algorithmes</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27092830</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>20</Day></DateCreated><DateCompleted><Year>2016</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>315</Volume><Issue>15</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.</ArticleTitle><Pagination><MedlinePgn>1600-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2016.4059</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma.</AbstractText><AbstractText Label="DESIGN, SETTINGS, AND PARTICIPANTS" NlmCategory="METHODS">Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic medical centers in Australia, Canada, France, and the United States. Eligible patients were aged 18 years and older and had advanced or metastatic melanoma. Data were pooled from 655 enrolled patients (135 from a nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ipilimumab treated] and 520 from randomized cohorts [n = 226 ipilimumab naive; n = 294 ipilimumab treated]). Cutoff dates were April 18, 2014, for safety analyses and October 18, 2014, for efficacy analyses.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks continued until disease progression, intolerable toxicity, or investigator decision.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The primary end point was confirmed objective response rate (best overall response of complete response or partial response) in patients with measurable disease at baseline per independent central review. Secondary end points included toxicity, duration of response, progression-free survival, and overall survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 655 patients (median [range] age, 61 [18-94] years; 405 [62%] men), 581 had measurable disease at baseline. An objective response was reported in 194 of 581 patients (33% [95% CI, 30%-37%]) and in 60 of 133 treatment-naive patients (45% [95% CI, 36% to 54%]). Overall, 74% (152/205) of responses were ongoing at the time of data cutoff; 44% (90/205) of patients had response duration for at least 1 year and 79% (162/205) had response duration for at least 6 months. Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total population and 52% (95% CI, 43%-60%) among treatment-naive patients. Median overall survival in the total population was 23 months (95% CI, 20-29) with a 12-month survival rate of 66% (95% CI, 62%-69%) and a 24-month survival rate of 49% (95% CI, 44%-53%). In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not reached) with a 12-month survival rate of 73% (95% CI, 65%-79%) and a 24-month survival rate of 60% (95% CI, 51%-68%). Ninety-two of 655 patients (14%) experienced at least 1 treatment-related grade 3 or 4 adverse event (AE) and 27 of 655 (4%) patients discontinued treatment because of a treatment-related AE. Treatment-related serious AEs were reported in 59 patients (9%). There were no drug-related deaths.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among patients with advanced melanoma, pembrolizumab administration was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treatment-related AEs occurred in 14%.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT01295827.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ribas</LastName><ForeName>Antoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, University of California-Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamid</LastName><ForeName>Omid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daud</LastName><ForeName>Adil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, University of California-San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodi</LastName><ForeName>F Stephen</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolchok</LastName><ForeName>Jedd D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kefford</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, Australia7Department of Clinical Medicine, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshua</LastName><ForeName>Anthony M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patnaik</LastName><ForeName>Amita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwu</LastName><ForeName>Wen-Jen</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Melanoma, The University of Texas MD Anderson Cancer Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gangadhar</LastName><ForeName>Tara C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Abramson Cancer Center at the University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hersey</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dronca</LastName><ForeName>Roxana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarour</LastName><ForeName>Hassane</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chmielowski</LastName><ForeName>Bartosz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, University of California-Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Donald P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Algazi</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, University of California-San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizvi</LastName><ForeName>Naiyer A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffner</LastName><ForeName>Brianna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateus</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gergich</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindia</LastName><ForeName>Jill A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannotti</LastName><ForeName>Maxine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoyun Nicole</ForeName><Initials>XN</Initials><AffiliationInfo><Affiliation>BARDS, Merck & Co, Inc, Kenilworth, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebbinghaus</LastName><ForeName>Scot</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>S Peter</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Merck & Co, Inc, Kenilworth, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave-Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01295827</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T8C155666</RegistryNumber><NameOfSubstance UI="C508317">ipilimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>DPT0O3T46P</RegistryNumber><NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2016 Apr 19;315(15):1573-5</RefSource><PMID Version="1">27092829</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA. 2016 Jun 14;315(22):2472</RefSource><PMID Version="1">27299632</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27092830</ArticleId><ArticleId IdType="pii">2514195</ArticleId><ArticleId IdType="doi">10.1001/jama.2016.4059</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Canada</li><li>France</li><li>États-Unis</li></country><region><li>Californie</li><li>Floride</li><li>Massachusetts</li><li>Minnesota</li><li>New Jersey</li><li>Nouvelle-Galles du Sud</li><li>Pennsylvanie</li><li>Texas</li><li>État de New York</li></region><settlement><li>Boston</li><li>Houston</li><li>Los Angeles</li><li>Philadelphie</li><li>San Francisco</li><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><noCountry><name sortKey="Patnaik, Amita" sort="Patnaik, Amita" uniqKey="Patnaik A" first="Amita" last="Patnaik">Amita Patnaik</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name></region><name sortKey="Algazi, Alain" sort="Algazi, Alain" uniqKey="Algazi A" first="Alain" last="Algazi">Alain Algazi</name><name sortKey="Chmielowski, Bartosz" sort="Chmielowski, Bartosz" uniqKey="Chmielowski B" first="Bartosz" last="Chmielowski">Bartosz Chmielowski</name><name sortKey="Daud, Adil" sort="Daud, Adil" uniqKey="Daud A" first="Adil" last="Daud">Adil Daud</name><name sortKey="Dronca, Roxana" sort="Dronca, Roxana" uniqKey="Dronca R" first="Roxana" last="Dronca">Roxana Dronca</name><name sortKey="Ebbinghaus, Scot" sort="Ebbinghaus, Scot" uniqKey="Ebbinghaus S" first="Scot" last="Ebbinghaus">Scot Ebbinghaus</name><name sortKey="Gangadhar, Tara C" sort="Gangadhar, Tara C" uniqKey="Gangadhar T" first="Tara C" last="Gangadhar">Tara C. Gangadhar</name><name sortKey="Gergich, Kevin" sort="Gergich, Kevin" uniqKey="Gergich K" first="Kevin" last="Gergich">Kevin Gergich</name><name sortKey="Giannotti, Maxine" sort="Giannotti, Maxine" uniqKey="Giannotti M" first="Maxine" last="Giannotti">Maxine Giannotti</name><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><name sortKey="Hodi, F Stephen" sort="Hodi, F Stephen" uniqKey="Hodi F" first="F Stephen" last="Hodi">F Stephen Hodi</name><name sortKey="Hoffner, Brianna" sort="Hoffner, Brianna" uniqKey="Hoffner B" first="Brianna" last="Hoffner">Brianna Hoffner</name><name sortKey="Hwu, Wen Jen" sort="Hwu, Wen Jen" uniqKey="Hwu W" first="Wen-Jen" last="Hwu">Wen-Jen Hwu</name><name sortKey="Joseph, Richard W" sort="Joseph, Richard W" uniqKey="Joseph R" first="Richard W" last="Joseph">Richard W. Joseph</name><name sortKey="Kang, S Peter" sort="Kang, S Peter" uniqKey="Kang S" first="S Peter" last="Kang">S Peter Kang</name><name sortKey="Lawrence, Donald P" sort="Lawrence, Donald P" uniqKey="Lawrence D" first="Donald P" last="Lawrence">Donald P. Lawrence</name><name sortKey="Li, Xiaoyun Nicole" sort="Li, Xiaoyun Nicole" uniqKey="Li X" first="Xiaoyun Nicole" last="Li">Xiaoyun Nicole Li</name><name sortKey="Lindia, Jill A" sort="Lindia, Jill A" uniqKey="Lindia J" first="Jill A" last="Lindia">Jill A. Lindia</name><name sortKey="Rizvi, Naiyer A" sort="Rizvi, Naiyer A" uniqKey="Rizvi N" first="Naiyer A" last="Rizvi">Naiyer A. Rizvi</name><name sortKey="Weber, Jeffrey S" sort="Weber, Jeffrey S" uniqKey="Weber J" first="Jeffrey S" last="Weber">Jeffrey S. Weber</name><name sortKey="Wolchok, Jedd D" sort="Wolchok, Jedd D" uniqKey="Wolchok J" first="Jedd D" last="Wolchok">Jedd D. Wolchok</name><name sortKey="Zarour, Hassane" sort="Zarour, Hassane" uniqKey="Zarour H" first="Hassane" last="Zarour">Hassane Zarour</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Kefford, Richard" sort="Kefford, Richard" uniqKey="Kefford R" first="Richard" last="Kefford">Richard Kefford</name></region><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name></country><country name="Canada"><noRegion><name sortKey="Joshua, Anthony M" sort="Joshua, Anthony M" uniqKey="Joshua A" first="Anthony M" last="Joshua">Anthony M. Joshua</name></noRegion></country><country name="France"><noRegion><name sortKey="Mateus, Christine" sort="Mateus, Christine" uniqKey="Mateus C" first="Christine" last="Mateus">Christine Mateus</name></noRegion><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003433 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003433 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27092830
|texte= Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27092830" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |